Advanced Enzyme

Why is Advanced Enzyme Technologies Ltd falling/rising?

As of 05-Aug, Advanced Enzyme Technologies Ltd's stock price has risen to 332.45, up 2.94%, driven by strong financial results, including a 51.14% increase in profit before tax and a net-debt free status, despite a decline in delivery volume. The stock has outperformed its sector and has strong institutional backing, indicating positive investor sentiment.

As of 05-Aug, Advanced Enzyme Technologies Ltd is experiencing a rise in its stock price, currently at 332.45, with a change of 9.5, representing an increase of 2.94%. This upward movement can be attributed to several positive factors highlighted in the recent performance data. <BR><BR>The stock has outperformed its sector by 3.03% today, indicating strong relative performance. Additionally, the stock reached an intraday high of Rs 337, reflecting a rise of 4.35% during the trading day. The company has reported impressive financial results, with a significant growth in profit before tax (PBT) of 51.14% and a profit after tax (PAT) growth of 61.9% for the most recent quarter. Furthermore, net sales have also shown a robust increase of 21.65%. <BR><BR>The company is net-debt free, which is a positive indicator of its financial health, and it has a high institutional holding of 31.49%, suggesting confidence from larger investors who typically conduct thorough analyses of company fundamentals. This institutional stake has even increased by 0.59% over the previous quarter, further supporting the stock's upward trajectory.<BR><BR>Despite a slight decline in investor participation, as indicated by a 16.46% drop in delivery volume compared to the 5-day average, the overall positive financial performance and strong institutional backing appear to be driving the stock's rise.

Which are the latest news on Advanced Enzyme?

How big is Advanced Enzyme?

As of 10th June, Advanced Enzyme Technologies Ltd has a market capitalization of 4,177.00 Cr, with recent net sales of 745.76 Cr and net profit of 168.72 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Advanced Enzyme Technologies Ltd has a market capitalization of 4,177.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 745.76 Cr, while the sum of Net Profit for the same period is 168.72 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 1,420.86 Cr and Total Assets totaling 1,611.15 Cr.

Who are in the management team of Advanced Enzyme?

The management team of Advanced Enzyme includes key members such as Mukund Madhusudan Kabra (Whole-time Director), Vasant Rathi (Chairman), and several independent directors, bringing diverse expertise and governance to the company.

The management team of Advanced Enzyme includes the following key members:<BR><BR>1. **Mukund Madhusudan Kabra** - Whole-time Director<BR>2. **Kedar Jagdish Desai** - Independent Director<BR>3. **Vasant Rathi** - Chairman (Non-Executive)<BR>4. **Pramod Kasat** - Independent Director<BR>5. **Sanjay Basantani** - Company Secretary & Compliance Officer<BR>6. **Rajesh Kumar Sharma** - Independent Director<BR>7. **Rasika Rathi** - Non-Executive & Non-Independent Director<BR>8. **Vindokumar Hiralal Jajoo** - Independent Director<BR>9. **Sunny Sharma** - Non-Executive & Non-Independent Director<BR>10. **Rajshree Patel** - Independent Director<BR>11. **Nitin Jagannath Deshmukh** - Independent Director<BR>12. **Vandana Tilak** - Independent Director<BR><BR>This team brings a diverse range of expertise and governance to the company.

Who are the peers of the Advanced Enzyme?

Peers of Advanced Enzyme include Senores Pharma, Bliss GVS Pharma, Orchid Pharma, Guj. Themis Bio, IOL Chemicals, RPG LifeScience, Gufic BioScience, SMS Pharma, and Panacea Biotec. Advanced Enzyme has average management risk, below average growth, and a 1-year return of 9.84%, lower than its peers.

Peers: The peers of Advanced Enzyme are Senores Pharma., Bliss GVS Pharma, Orchid Pharma, Guj. Themis Bio., IOL Chemicals, RPG LifeScience., Gufic BioScience, SMS Pharma., and Panacea Biotec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Senores Pharma., Guj. Themis Bio., and IOL Chemicals, while Average management risk is found at Bliss GVS Pharma, RPG LifeScience., Gufic BioScience, SMS Pharma., and Advanced Enzyme. Below Average management risk is noted at Orchid Pharma and Panacea Biotec. For Growth, Excellent growth is seen at Senores Pharma., while Below Average growth is present at Bliss GVS Pharma, Orchid Pharma, Guj. Themis Bio., Advanced Enzyme, IOL Chemicals, RPG LifeScience., Gufic BioScience, SMS Pharma., and Panacea Biotec. Good capital structure is found at Guj. Themis Bio., while Excellent capital structure is noted at Bliss GVS Pharma, IOL Chemicals, RPG LifeScience., and Advanced Enzyme, and Average capital structure is seen at Gufic BioScience and SMS Pharma., with Below Average capital structure at Orchid Pharma and Panacea Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Senores Pharma. at 116.97%, while the lowest is Panacea Biotec at 17.12%. Advanced Enzyme's 1-year return is 9.84%, which is lower than both of these peers. Additionally, Orchid Pharma and Guj. Themis Bio. have negative six-month returns.

What does Advanced Enzyme do?

Advanced Enzyme Technologies Ltd is India's largest enzyme manufacturer in the Pharmaceuticals & Biotechnology sector, with a market cap of INR 4,177 Cr and reported net sales of 203 Cr and net profit of 43 Cr for March 2026. The company has a P/E ratio of 26.00 and a dividend yield of 0.32%.

Overview:<BR>Advanced Enzyme Technologies Ltd is the largest Indian enzyme company engaged in the manufacturing and sale of enzymes, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap.<BR><BR>History:<BR>The company was incorporated in 1989 as 'Advanced Biochemicals Private Limited' and later became a public company, changing its name to Advanced Biochemicals Limited in 1992. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 203 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 43 Cr (Quarterly Results - Mar 2026)<BR>- Market cap: INR 4,177 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 26.00<BR>- Industry P/E: 42<BR>- Dividend Yield: 0.32%<BR>- Debt Equity: -0.41<BR>- Return on Equity: 9.82%<BR>- Price to Book: 2.55<BR><BR>Contact Details:<BR>Address: Sun Magnetica 5th Floor, Nr LIC Service Road Louiswadi Thane Maharashtra : 400604<BR>Tel: 91-22-41703200<BR>Email: info@advancedenzymes.com<BR>Website: http://www.advancedenzymes.com

Are Advanced Enzyme Technologies Ltd latest results good or bad?

Advanced Enzyme Technologies Ltd's latest Q4 FY26 results are strong, with a 62.24% increase in net profit and a 21.65% rise in net sales. However, concerns about low return on equity and margin consistency suggest that investors should be cautious despite the positive growth.

Advanced Enzyme Technologies Ltd's latest results for Q4 FY26 indicate a strong performance overall. The company reported a consolidated net profit of ₹42.96 crores, which represents a significant year-on-year increase of 62.24%. Additionally, net sales reached ₹203.37 crores, marking a 21.65% increase compared to the same quarter last year. This quarter also saw an improvement in operating margins, which rose to 31.09%, up from 27.28% in the previous year.<BR><BR>Despite these positive indicators, there are some concerns. The return on equity (ROE) stands at 9.93%, which is below industry standards, raising questions about capital efficiency. Furthermore, the stock has shown modest gains recently and is trading at ₹357.30, reflecting a slight decline on the day but a notable increase of 28.06% over the past year.<BR><BR>In summary, while the latest quarterly results showcase strong growth in profit and sales, the company's challenges with margin consistency and return ratios suggest that investors should remain cautious. The overall performance is good, but the underlying issues warrant careful consideration.

Should I buy, sell or hold Advanced Enzyme Technologies Ltd?

Is Advanced Enzyme technically bullish or bearish?

As of December 1, 2025, the technical trend for Advanced Enzyme has shifted to mildly bearish, driven by bearish MACD readings and Bollinger Bands, despite some mixed signals from daily moving averages and RSI.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven primarily by the weekly and monthly MACD readings, both indicating bearish momentum. The Bollinger Bands also reflect a mildly bearish outlook on both weekly and monthly time frames. Although the daily moving averages show a mildly bullish signal, this is overshadowed by the bearish signals from the KST and the overall trend change. The RSI presents a mixed picture with no signal on the weekly and bullish on the monthly, but the lack of a clear trend in Dow Theory and OBV further supports the bearish stance. Overall, the indicators suggest a weak bearish sentiment in the current market environment for Advanced Enzyme.

How has been the historical performance of Advanced Enzyme?

Advanced Enzyme has shown consistent growth in net sales, increasing from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25, but faced rising expenditures leading to a decline in operating profit and net profit. Total assets and liabilities both grew to 1,611.15 Cr by Mar'25, while cash flow from operations remained stable despite a net cash outflow of -19 Cr.

Answer:<BR>The historical performance of Advanced Enzyme shows a consistent growth in net sales and total operating income over the years, with net sales increasing from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25. The total operating income followed a similar trend, rising from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25. However, the total expenditure has also increased, reaching 442.47 Cr in Mar'25 from 237.67 Cr in Mar'19, which has impacted the operating profit, which decreased from 240.46 Cr in Mar'21 to 227.48 Cr in Mar'25. The profit before tax showed fluctuations, peaking at 210.13 Cr in Mar'21 and slightly declining to 187.36 Cr in Mar'25. The profit after tax also experienced a decline from 151.29 Cr in Mar'21 to 133.97 Cr in Mar'25. The earnings per share (EPS) decreased from 13.06 in Mar'21 to 11.72 in Mar'25, reflecting the overall profit trend. On the balance sheet, total assets grew from 971.18 Cr in Mar'20 to 1,611.15 Cr in Mar'25, while total liabilities increased from 971.18 Cr to 1,611.15 Cr in the same period. Cash flow from operating activities remained relatively stable, with a slight increase from 140 Cr in Mar'23 to 142 Cr in Mar'25, although the net cash outflow was recorded at -19 Cr in Mar'25.<BR><BR>Breakdown:<BR>Advanced Enzyme has demonstrated a robust growth trajectory in net sales, which rose from 419.59 Cr in Mar'19 to 636.91 Cr in Mar'25, indicating a strong demand for its products. The total operating income mirrored this growth, reaching 636.91 Cr in Mar'25. Despite this growth, total expenditure also increased significantly, leading to a decline in operating profit from 240.46 Cr in Mar'21 to 227.48 Cr in Mar'25. Profit before tax fluctuated, peaking at 210.13 Cr in Mar'21 before settling at 187.36 Cr in Mar'25, while profit after tax decreased from 151.29 Cr in Mar'21 to 133.97 Cr in Mar'25. The EPS followed a similar downward trend, dropping from 13.06 to 11.72 over the same period. On the balance sheet, total assets and liabilities both grew to 1,611.15 Cr by Mar'25, reflecting the company's expanding operations. Cash flow from operating activities remained stable, although the company faced a net cash outflow of -19 Cr in Mar'25, highlighting challenges in cash management despite operational profitability.

Is Advanced Enzyme overvalued or undervalued?

As of July 30, 2020, Advanced Enzyme is considered very expensive and overvalued with a PE ratio of 25.89, despite outperforming the Sensex in the short term, while its year-to-date performance is down by 10.37%.

As of 30 July 2020, the valuation grade for Advanced Enzyme moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE ratio of 25.89, an EV to EBITDA of 14.64, and a Price to Book Value of 2.39, all of which suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Advanced Enzyme's PE ratio is notably lower than Solar Industries at 123.77 and Gujarat Fluoroch at 73.59, both of which are also classified as very expensive. However, it is significantly higher than Godrej Industries, which is rated attractive with a PE of 46.63. The recent stock performance shows a 1-month return of 11.21%, outperforming the Sensex's 3.87% return, but the year-to-date performance is down by 10.37%, contrasting with the Sensex's gain of 5.62%. This mixed performance further supports the conclusion of overvaluation.

Who are the top shareholders of the Advanced Enzyme?

The top shareholders of Advanced Enzyme include promoters holding the majority of shares, with Vasant Rathi having the largest stake at 33.18%. Additionally, mutual funds own 5.36%, foreign institutional investors hold 11.9%, and individual investors collectively own 16.68%.

The top shareholders of Advanced Enzyme include the promoters, who hold the majority of the shares. Notably, Vasant Rathi is the promoter with the highest holding at 33.18%. Additionally, the company has 9 mutual fund schemes holding a combined 5.36% and 70 foreign institutional investors (FIIs) holding 11.9%. Individual investors collectively hold 16.68% of the shares. The highest public shareholder is Orbimed Asia III Mauritius Fvci Limited, which holds 0%. There are no pledged promoter holdings reported.

When is the next results date for Advanced Enzyme?

No Upcoming Board Meetings

Has Advanced Enzyme declared dividend?

Yes, Advanced Enzyme Technologies Ltd has declared a dividend of 200%, amounting to ₹4 per share, with an ex-date of May 16, 2025. The dividend yield is 1.68%, and while recent returns have been volatile, the total return over the past five years is 104.53%.

Advanced Enzyme Technologies Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 4<BR>- Ex-date: May 16, 2025<BR><BR>Dividend Yield: 1.68%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -19.63%, the dividend return was 1.02%, resulting in a total return of -18.61%.<BR><BR>Over the past year, the price return was -15.92%, with a dividend return of 1.41%, leading to a total return of -14.51%.<BR><BR>In the 2-year period, the price return was 8.5%, the dividend return was 3.69%, culminating in a total return of 12.19%.<BR><BR>For the 3-year period, the price return stood at 1.81%, the dividend return was 5.62%, resulting in a total return of 7.43%.<BR><BR>In the last 4 years, the price return was -26.95%, while the dividend return was 3.89%, leading to a total return of -23.06%.<BR><BR>Finally, over the past 5 years, the price return was 94.86%, the dividend return was 9.67%, resulting in a total return of 104.53%.<BR><BR>Overall, Advanced Enzyme Technologies Ltd has declared a significant dividend, and while recent returns have shown volatility, the long-term performance over five years indicates a strong total return driven by both price appreciation and dividends.